Viewing StudyNCT06182592

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:55 PM
Last Modification Date: 2024-10-26 @ 3:16 PM
Study NCT ID: NCT06182592
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-12-28
First Post: 2023-12-13
Brief Title: A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk Secondary Acute Myeloid Leukemia
Sponsor: CSPC Zhongnuo Pharmaceutical Shijiazhuang Co Ltd
Organization: CSPC Zhongnuo Pharmaceutical Shijiazhuang Co Ltd
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
High-risk Secondary Acute Myeloid Leukemia
Keywords: